title: Cardiovascular risk assessment of the liver transplant candidate.
abstract: Liver transplantation (LT) candidates today are increasingly older, have greater medical acuity, and have more cardiovascular comorbidities than ever before. Steadily rising model for end-stage liver disease (MELD) scores at the time of transplant, resulting from high organ demand, reflect the escalating risk profiles of LT candidates. In addition to advanced age and the presence of comorbidities, there are specific cardiovascular responses in cirrhosis that can be detrimental to the LT candidate. Patients with cirrhosis requiring LT usually demonstrate increased cardiac output and a compromised ventricular response to stress, a condition termed cirrhotic cardiomyopathy. These cardiac disturbances are likely mediated by decreased beta-agonist transduction, increased circulating inflammatory mediators with cardiodepressant properties, and repolarization changes. Low systemic vascular resistance and bradycardia are also commonly seen in cirrhosis and can be aggravated by beta-blocker use. These physiologic changes all contribute to the potential for cardiovascular complications, particularly with the altered hemodynamic stresses that LT patients face in the immediate post-operative period. Post-transplant reperfusion may result in cardiac death due to a multitude of causes, including arrhythmia, acute heart failure, and myocardial infarction. Recognizing the hemodynamic challenges encountered by LT patients in the perioperative period and how these responses can be exacerbated by underlying cardiac pathology is critical in developing recommendations for the pre-operative risk assessment and management of these patients. The following provides a review of the cardiovascular challenges in LT candidates, as well as evidence-based recommendations for their evaluation and management.
authors: Department of Medicine, Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA.
authors: Zankhana
authors: Z
authors: Raval
authors: Matthew E
authors: ME
authors: Harinstein
authors: Anton I
authors: AI
authors: Skaro
authors: Ata
authors: A
authors: Erdogan
authors: Andre M
authors: AM
authors: DeWolf
authors: Sanjiv J
authors: SJ
authors: Shah
authors: Oren K
authors: OK
authors: Fix
authors: Nina
authors: N
authors: Kay
authors: Michael I
authors: MI
authors: Abecassis
authors: Mihai
authors: M
authors: Gheorghiade
authors: James D
authors: JD
authors: Flaherty
mesh_terms: D000818:Animals; D009202:Cardiomyopathies / Q000150:complications / Q000175:diagnosis; D002318:Cardiovascular Diseases / Q000175:diagnosis* / Q000503:physiopathology; D002319:Cardiovascular System / Q000503:physiopathology*; D003324:Coronary Artery Disease / Q000150:complications / Q000175:diagnosis / Q000503:physiopathology; D054092:Foramen Ovale, Patent / Q000150:complications / Q000175:diagnosis; D006333:Heart Failure / Q000150:complications / Q000175:diagnosis; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications / Q000503:physiopathology / Q000601:surgery*; D017114:Liver Failure, Acute / Q000150:complications / Q000601:surgery; D016031:Liver Transplantation; D008133:Long QT Syndrome / Q000150:complications* / Q000175:diagnosis; D010490:Pericardial Effusion / Q000150:complications / Q000175:diagnosis; D011183:Postoperative Complications; D011660:Pulmonary Heart Disease / Q000150:complications / Q000175:diagnosis; D018570:Risk Assessment; D012307:Risk Factors